What is the recommended dosing schedule for Wegovy (semaglutide) 0.5 mg?

Wegovy 0.5 mg Dosing Schedule

Wegovy 0.5 mg is an escalation dose administered once weekly for 4 weeks (weeks 5-8), not a maintenance dose—you must continue titrating to reach the therapeutic target of 2.4 mg weekly. 1

Standard Dose Escalation Protocol

The FDA-approved titration schedule for Wegovy follows a structured 16-week escalation to minimize gastrointestinal adverse effects 1:

Weeks 1-4: 0.25 mg once weekly (initiation dose)
Weeks 5-8: 0.5 mg once weekly (first escalation)
Weeks 9-12: 1.0 mg once weekly (second escalation)
Weeks 13-16: 1.7 mg once weekly (third escalation)
Week 17 onward: 2.4 mg once weekly (recommended maintenance dose)

Key Administration Points

• Administer subcutaneously in abdomen, thigh, or upper arm 1
• Inject on the same day each week, any time of day, with or without meals 1
• Must be combined with reduced-calorie diet and increased physical activity 1

Dose Modification Strategies

If gastrointestinal intolerance occurs: Delay dose escalation by 4 weeks at the current dose level 2. This gradual titration approach is critical—nausea occurs in 17-44% of patients and vomiting in 7-25% with semaglutide 3, 2.

For missed doses:

• If next dose is >48 hours away: administer immediately
• If next dose is <48 hours away: skip and resume regular schedule
• If ≥2 consecutive doses missed: consider restarting titration schedule 1

Maintenance Dosing Considerations

While 2.4 mg weekly is the recommended maintenance dose for maximal weight loss (mean 14.9% body weight reduction), 1.7 mg weekly is an acceptable alternative maintenance dose if the higher dose is not tolerated 1. Real-world data shows approximately 40% of patients remain on ≤1.0 mg weekly, though this represents suboptimal dosing 4.

Clinical judgment is warranted: Some patients achieve strong response at submaximal doses and may continue long-term at lower maintenance doses 2.

Critical Safety Monitoring

• Monitor blood glucose if patient has type 2 diabetes—adjust insulin or sulfonylurea doses to prevent hypoglycemia 1
• Assess hydration status during dose escalation, particularly with severe GI symptoms, to prevent acute kidney injury 1
• Contraindicated in personal/family history of medullary thyroid carcinoma or MEN 2 syndrome 1

Common Pitfalls to Avoid

1. Do not remain at 0.5 mg long-term—this is not a therapeutic dose for obesity management
2. Do not skip the titration schedule—jumping directly to higher doses dramatically increases GI adverse events
3. Do not combine with other GLP-1 receptor agonists or DPP-4 inhibitors 2
4. Discontinue at least 2 months before planned pregnancy due to long half-life 1

The 0.5 mg dose represents only the second step in a mandatory 16-week titration protocol designed to balance efficacy with tolerability, ultimately targeting 2.4 mg weekly for optimal weight reduction and cardiovascular risk reduction 1.